Enhance Your Cell Line Development Efficiency With Our AbZelect™ Platforms

Our AbZelectPRO™ platform supports the efficient and stable production of difficult-to-express therapies like fusion proteins, bispecifics and other novel modalities by combining ProteoNic's 2G UNic® premium vector technology with AbZelect™. Offering a unique double promoter to drive gene expression and enhance messenger RNA stability, the AbZelectPRO™ platform can achieve higher viable cell density (VCD) and productivity in comparison with the AbZelect™ platform.  

The AbZelect™ platform allows for efficient generation of early-stage material enhancing productivity at both pool and clonal stages whereas the unique double promoter-driven gene expression of AbZelectPro™ builds on the AbZelect™ capabilities to provide higher viable cell density and productivity. The AbZelectPro™ platform achieves this by combining the capabilities of AbZelect™ with 2G UNic® premium vector technology to generate higher-producing, stable cell lines for difficult-to-express proteins, including bispecifics, fusions and other novel modalities.

Efficient tech transfer is a common area of focus when relying on a contract development and manufacturing organization (CDMO) for support, being critical for the smooth transition of projects from CLD into manufacturing. Operating across our sites in Cambridge, UK, and San Diego, US, our teams work closely together to ensure the seamless progression of your project. Our extensive experience and collaborative culture allow us to proactively identify and prevent risks that could delay your therapy reaching patients.  

By integrating fully automated, next-generation technologies such as the Cyto-Mine® high-throughput microfluidics screening platform into AbZelect™ and AbZelectPRO™, we can rapidly select high-performing clones while ensuring monoclonality. The Cyto-Mine® platform provides productivity data on a per-cell basis, allowing us to rank individual clones and select single cells with the highest productivity for further expansion and characterization. 

The AbZelect™ platforms are designed to provide the flexibility needed to support your unique antibody-based therapy, whether that’s a monoclonal antibody (mAb), bispecific antibody, fusion protein or novel modality. Leveraging our analytical development and regulatory expertise, we can adapt our testing methods or develop new assays to safeguard the quality of your therapy from CLD to manufacturing.